Descriptions

The glp-1 protein is an essential signaling protein which has a major role in the induction of germ-line proliferation and for embryogenesis. Truncation of the C-terminal region activates glp-1 protein to specify vulval fates in C. elegans. In addition, C-terminal truncation may either destroy a more specific negative regulatory domain, thereby depressing normal glp-1 activity, or alter the specificity such that the mutant of glp-1 can interact with factors that the normal glp-1 product cannot.
Upon ligand activation and releasing from the cell membrane, intracellular domains probably forms a transcriptional activator complex with lag-1 and lag-3 and regulates expression of various genes.

Autoinhibitory domains (AIDs)

Target domain

797-858 (RAM domain); 886-1168 (Ankyrin repeats)

Relief mechanism

Assay

Deletion assay

Accessory elements

No accessory elements

Autoinhibited structure

Activated structure

1 structures for P13508

Entry ID Method Resolution Chain Position Source
AF-P13508-F1 Predicted AlphaFoldDB

No variants for P13508

Variant ID(s) Position Change Description Diseaes Association Provenance
No variants for P13508

6 associated diseases with P13508

[MIM: 603689]: Myopathy, myofibrillar, 9, with early respiratory failure (MFM9)

An autosomal dominant myopathy characterized by adulthood onset of weakness in proximal, distal, axial and respiratory muscles. Pelvic girdle weakness, foot drop and neck weakness are the main symptoms at onset, but ultimately the weakness usually involves the proximal compartment of both upper and lower limbs. Additional features include variable degrees of Achilles tendon contractures, spinal rigidity and muscle hypertrophy. Respiratory involvement often leads to requirement for non-invasive ventilation support. . Note=The disease is caused by variants affecting the gene represented in this entry.

[MIM: 613765]: Cardiomyopathy, familial hypertrophic, 9 (CMH9)

A hereditary heart disorder characterized by ventricular hypertrophy, which is usually asymmetric and often involves the interventricular septum. The symptoms include dyspnea, syncope, collapse, palpitations, and chest pain. They can be readily provoked by exercise. The disorder has inter- and intrafamilial variability ranging from benign to malignant forms with high risk of cardiac failure and sudden cardiac death. . Note=The disease is caused by variants affecting the gene represented in this entry.

[MIM: 604145]: Cardiomyopathy, dilated, 1G (CMD1G)

A disorder characterized by ventricular dilation and impaired systolic function, resulting in congestive heart failure and arrhythmia. Patients are at risk of premature death. . Note=The disease is caused by variants affecting the gene represented in this entry.

[MIM: 600334]: Tardive tibial muscular dystrophy (TMD)

Autosomal dominant, late-onset distal myopathy. Muscle weakness and atrophy are usually confined to the anterior compartment of the lower leg, in particular the tibialis anterior muscle. Clinical symptoms usually occur at age 35-45 years or much later. . Note=The disease is caused by variants affecting the gene represented in this entry.

[MIM: 608807]: Muscular dystrophy, limb-girdle, autosomal recessive 10 (LGMDR10)

An autosomal recessive degenerative myopathy characterized by progressive weakness of the pelvic and shoulder girdle muscles. Severe disability is observed within 20 years of onset. . Note=The disease is caused by variants affecting the gene represented in this entry.

[MIM: 611705]: Congenital myopathy 5 with cardiomyopathy (CMYP5)

An autosomal recessive, early-onset muscular disorder characterized by dilated cardiomyopathy, delayed motor development with generalized muscle weakness predominantly affecting proximal and distal lower limbs. Skeletal muscle biopsies show minicore-like lesions with mitochondrial depletion and sarcomere disorganization, centralized nuclei, and type 1 fiber predominance. Dystrophic changes become apparent in the second decade. Cardiac muscle biopsies show disruption of myocardial architecture, nuclear hypertrophy, and endomysial fibrosis. Sudden death may occurr due to cardiomyopathy. . Note=The disease is caused by variants affecting the gene represented in this entry.

Without disease ID
  • An autosomal dominant myopathy characterized by adulthood onset of weakness in proximal, distal, axial and respiratory muscles. Pelvic girdle weakness, foot drop and neck weakness are the main symptoms at onset, but ultimately the weakness usually involves the proximal compartment of both upper and lower limbs. Additional features include variable degrees of Achilles tendon contractures, spinal rigidity and muscle hypertrophy. Respiratory involvement often leads to requirement for non-invasive ventilation support. . Note=The disease is caused by variants affecting the gene represented in this entry.
  • A hereditary heart disorder characterized by ventricular hypertrophy, which is usually asymmetric and often involves the interventricular septum. The symptoms include dyspnea, syncope, collapse, palpitations, and chest pain. They can be readily provoked by exercise. The disorder has inter- and intrafamilial variability ranging from benign to malignant forms with high risk of cardiac failure and sudden cardiac death. . Note=The disease is caused by variants affecting the gene represented in this entry.
  • A disorder characterized by ventricular dilation and impaired systolic function, resulting in congestive heart failure and arrhythmia. Patients are at risk of premature death. . Note=The disease is caused by variants affecting the gene represented in this entry.
  • Autosomal dominant, late-onset distal myopathy. Muscle weakness and atrophy are usually confined to the anterior compartment of the lower leg, in particular the tibialis anterior muscle. Clinical symptoms usually occur at age 35-45 years or much later. . Note=The disease is caused by variants affecting the gene represented in this entry.
  • An autosomal recessive degenerative myopathy characterized by progressive weakness of the pelvic and shoulder girdle muscles. Severe disability is observed within 20 years of onset. . Note=The disease is caused by variants affecting the gene represented in this entry.
  • An autosomal recessive, early-onset muscular disorder characterized by dilated cardiomyopathy, delayed motor development with generalized muscle weakness predominantly affecting proximal and distal lower limbs. Skeletal muscle biopsies show minicore-like lesions with mitochondrial depletion and sarcomere disorganization, centralized nuclei, and type 1 fiber predominance. Dystrophic changes become apparent in the second decade. Cardiac muscle biopsies show disruption of myocardial architecture, nuclear hypertrophy, and endomysial fibrosis. Sudden death may occurr due to cardiomyopathy. . Note=The disease is caused by variants affecting the gene represented in this entry.

5 regional properties for P13508

Type Name Position InterPro Accession
domain Protein kinase domain 735 - 996 IPR000719
domain Serine-threonine/tyrosine-protein kinase, catalytic domain 739 - 991 IPR001245
active_site Tyrosine-protein kinase, active site 854 - 866 IPR008266
binding_site Protein kinase, ATP binding site 741 - 767 IPR017441
domain Tyrosine-protein kinase, catalytic domain 735 - 993 IPR020635

Functions

Description
EC Number
Subcellular Localization
  • Cell membrane ; Single-pass type I membrane protein
  • Cell projection, axon
  • Localized to axons during dauer larval stage
PANTHER Family PTHR24049 CRUMBS FAMILY MEMBER
PANTHER Subfamily PTHR24049:SF22 DROSOPHILA CRUMBS HOMOLOG
PANTHER Protein Class cell adhesion molecule
PANTHER Pathway Category No pathway information available

8 GO annotations of cellular component

Name Definition
axon The long process of a neuron that conducts nerve impulses, usually away from the cell body to the terminals and varicosities, which are sites of storage and release of neurotransmitter.
cytoplasm The contents of a cell excluding the plasma membrane and nucleus, but including other subcellular structures.
cytosol The part of the cytoplasm that does not contain organelles but which does contain other particulate matter, such as protein complexes.
endomembrane system A collection of membranous structures involved in transport within the cell. The main components of the endomembrane system are endoplasmic reticulum, Golgi bodies, vesicles, cell membrane and nuclear envelope. Members of the endomembrane system pass materials through each other or though the use of vesicles.
lateral plasma membrane The portion of the plasma membrane at the lateral side of the cell. In epithelial cells, lateral plasma membranes are on the sides of cells which lie at the interface of adjacent cells.
plasma membrane The membrane surrounding a cell that separates the cell from its external environment. It consists of a phospholipid bilayer and associated proteins.
RNA polymerase II transcription regulator complex A transcription factor complex that acts at a regulatory region of a gene transcribed by RNA polymerase II.
spanning component of plasma membrane The component of the plasma membrane consisting of gene products and protein complexes that have some part that spans both leaflets of the membrane.

4 GO annotations of molecular function

Name Definition
calcium ion binding Binding to a calcium ion (Ca2+).
RNA polymerase II-specific DNA-binding transcription factor binding Binding to a sequence-specific DNA binding RNA polymerase II transcription factor, any of the factors that interact selectively and non-covalently with a specific DNA sequence in order to modulate transcription.
transcription coactivator activity A transcription coregulator activity that activates or increases the transcription of specific gene sets via binding to a DNA-bound DNA-binding transcription factor, either on its own or as part of a complex. Coactivators often act by altering chromatin structure and modifications. For example, one class of transcription coactivators modifies chromatin structure through covalent modification of histones. A second class remodels the conformation of chromatin in an ATP-dependent fashion. A third class modulates interactions of DNA-bound DNA-binding transcription factors with other transcription coregulators. A fourth class of coactivator activity is the bridging of a DNA-binding transcription factor to the general (basal) transcription machinery. The Mediator complex, which bridges sequence-specific DNA binding transcription factors and RNA polymerase, is also a transcription coactivator.
transmembrane signaling receptor activity Combining with an extracellular or intracellular signal and transmitting the signal from one side of the membrane to the other to initiate a change in cell activity or state as part of signal transduction.

17 GO annotations of biological process

Name Definition
cell fate specification The process involved in the specification of cell identity. Once specification has taken place, a cell will be committed to differentiate down a specific pathway if left in its normal environment.
cellularization The separation of a multi-nucleate cell or syncytium into individual cells. An example of this is found in Drosophila melanogaster embryo development.
cytoplasmic streaming The directed flow of cytosol (the liquid component of the cytoplasm) and the organelles it contains.
embryonic pattern specification The process that results in the patterns of cell differentiation that will arise in an embryo.
maintenance of dauer Maintenance of a nematode during the facultative diapause of the dauer (enduring) larval stage of nematode development.
negative regulation of stem cell differentiation Any process that stops, prevents or reduces the frequency, rate or extent of stem cell differentiation.
nematode larval development The process whose specific outcome is the progression of the nematode larva over time, from its formation to the mature structure. Nematode larval development begins with the newly hatched first-stage larva (L1) and ends with the end of the last larval stage (for example the fourth larval stage (L4) in C. elegans). Each stage of nematode larval development is characterized by proliferation of specific cell lineages and an increase in body size without alteration of the basic body plan. Nematode larval stages are separated by molts in which each stage-specific exoskeleton, or cuticle, is shed and replaced anew.
Notch signaling pathway The series of molecular signals initiated by an extracellular ligand binding to the receptor Notch on the surface of a target cell, and ending with the regulation of a downstream cellular process, e.g. transcription.
oocyte growth The developmental growth process in which an oocyte irreversibly increases in size over time by accretion and biosynthetic production of matter similar to that already present.
pharyngeal muscle development The process whose specific outcome is the progression of the pharyngeal muscle over time, from its formation to the mature structure. A pharyngeal muscle is any muscle that forms part of the pharynx.
positive regulation of germ cell proliferation Any process that activates or increases the frequency, rate or extent of germ cell proliferation.
positive regulation of stem cell proliferation Any process that activates or increases the frequency, rate or extent of stem cell proliferation.
positive regulation of transcription by RNA polymerase II Any process that activates or increases the frequency, rate or extent of transcription from an RNA polymerase II promoter.
posttranscriptional regulation of gene expression Any process that modulates the frequency, rate or extent of gene expression after the production of an RNA transcript.
regulation of gene expression Any process that modulates the frequency, rate or extent of gene expression. Gene expression is the process in which a gene's coding sequence is converted into a mature gene product (protein or RNA).
regulation of germ cell proliferation Any process that modulates the frequency, rate or extent of germ cell proliferation.
regulation of transcription by RNA polymerase II Any process that modulates the frequency, rate or extent of transcription mediated by RNA polymerase II.

13 homologous proteins in AiPD

UniProt AC Gene Name Protein Name Species Evidence Code
Q868Z9 Ppn Papilin Drosophila melanogaster (Fruit fly) SS
P21941 MATN1 Cartilage matrix protein Homo sapiens (Human) PR
P46531 NOTCH1 Neurogenic locus notch homolog protein 1 Homo sapiens (Human) EV
Q04721 NOTCH2 Neurogenic locus notch homolog protein 2 Homo sapiens (Human) EV
Q6GUQ1 Egfl8 Epidermal growth factor-like protein 8 Mus musculus (Mouse) PR
Q91V88 Npnt Nephronectin Mus musculus (Mouse) PR
P51942 Matn1 Cartilage matrix protein Mus musculus (Mouse) PR
O35516 Notch2 Neurogenic locus notch homolog protein 2 Mus musculus (Mouse) SS
Q01705 Notch1 Neurogenic locus notch homolog protein 1 Mus musculus (Mouse) SS
Q07008 Notch1 Neurogenic locus notch homolog protein 1 Rattus norvegicus (Rat) SS
Q9QW30 Notch2 Neurogenic locus notch homolog protein 2 Rattus norvegicus (Rat) SS
A2RUV0 notch1 Neurogenic locus notch homolog protein 1 Xenopus tropicalis (Western clawed frog) (Silurana tropicalis) SS
P46530 notch1a Neurogenic locus notch homolog protein 1 Danio rerio (Zebrafish) (Brachydanio rerio) SS
10 20 30 40 50 60
MRVLLILLAF FAPIASQLMG GECGREGACS VNGKCYNGKL IETYWCRCKK GFGGAFCERE
70 80 90 100 110 120
CDLDCKRGEK CIYDVYGENP TCICQDCEDE TPPTERTQKG CEEGYGGPDC KTPLFSGVNP
130 140 150 160 170 180
CDSDPCNNGL CYPFYGGFQC ICNNGYGGSY CEEGIDHCAQ NECAEGSTCV NSVYNYYCDC
190 200 210 220 230 240
PIGKSGRYCE RTECALMGNI CNHGRCIPNR DEDKNFRCVC DSGYEGEFCN KDKNECLIEE
250 260 270 280 290 300
TCVNNSTCFN LHGDFTCTCK PGYAGKYCEE AIDMCKDYVC QNDGYCAHDS NQMPICYCEQ
310 320 330 340 350 360
GFTGQRCEIE CPSGFGGIHC DLPLQRPHCS RSNGTCYNDG RCINGFCVCE PDYIGDRCEI
370 380 390 400 410 420
NRKDFKFPDI QSCKYNPCVN NATCIDLKNS GYSCHCPLGF YGLNCEQHLL CTPTTCANGG
430 440 450 460 470 480
TCEGVNGVIR CNCPNGFSGD YCEIKDRQLC SRHPCKNGGV CKNTGYCECQ YGYTGPTCEE
490 500 510 520 530 540
VLVIEKSKET VIRDLCEQRK CMDLASNGIC NPECNLEECN FDGGDCSGGQ RPFSKCQYPA
550 560 570 580 590 600
RCADQFANGV CNQECNNEEC LYDGLDCQSE LFRCPAHIRK HCIERRGDGV CNLECSFIGC
610 620 630 640 650 660
GFDGGDCNNG TEAIILSDIR IKVQIDPIEF QATGGETLMQ ISANLRATVR IQRDELGPLV
670 680 690 700 710 720
FRWDGEHEME RVEMNSSKLE DQFVLSHHVR RYRQAVVTGI VLYLEVEEIC KPEFCRFSTA
730 740 750 760 770 780
QSVVDLIAAG LVKSDGRMSL GLPITEAMVA VPKRNEIDEG WSRSQVILFA CIAFLAFGTV
790 800 810 820 830 840
VAGVIAKNGP ERSRKRKMVN ATVWMPPMES TNEKGRRNQS NHSSQCSLLD NSAYYHPNTK
850 860 870 880 890 900
RHCSDYSTGY NGEQYSQIYP QTLANGYPGD YNELNFDFQS ETFAPADLPA DEIPLHVQAA
910 920 930 940 950 960
GPDAITAPIT NESVNQVDSK YRRRVLHWLA ANVRGKPEDV ITTEAIRCLK AGADVNARDC
970 980 990 1000 1010 1020
DENTALMLAV RAHRVRLSVV LLREGANPTI FNNSERSALH EAVVNKDLRI LRHLLTDKRL
1030 1040 1050 1060 1070 1080
LKEIDELDRN GMTALMLVAR ELGKHQVEMA ELLLSKGAKL DYDGAARKDS NKYKGRTALH
1090 1100 1110 1120 1130 1140
YAAMHDNEEM VIMLVRRSSN KDKQDEDGRT PIMLAAKEGC EKTVQYLALN DASLGIVDSM
1150 1160 1170 1180 1190 1200
DMTAAQVAEA SYHHELAAFL RQVANERHRN DIMRQQIVKS GHGAKSGRQT VKNIKRAGSR
1210 1220 1230 1240 1250 1260
KTPTSAASSR ETNHLTPPPS DGSFSSPSPH YYPTTTSTPN RMETSPEYMF NHEMAPPVNA
1270 1280 1290
MWYTTPPPYQ DPNYRHVPPN TAFQNAEQMN GSFYC